Tweet
Brighton Jones LLC raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 12.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,878 shares of the biopharmaceutical company's stock after buying an additional 1,429 shares during the quarter. Brighton Jones LLC's holdings in Bristol-Myers Squibb were worth $713,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Global X Management Co. LLC grew its holdings in Bristol-Myers Squibb by 18.6% in the 1st quarter. Global X Management Co. LLC now owns 7,049 shares of the biopharmaceutical company's stock valued at $446,000 after buying an additional 1,104 shares during the last quarter. Benedict Financial Advisors Inc. grew its holdings in Bristol-Myers Squibb by 22.4% in the 1st quarter. Benedict Financial Advisors Inc. now owns 20,503 shares of the biopharmaceutical company's stock valued at $1,297,000 after buying an additional 3,752 shares during the last quarter. FDx Advisors Inc. grew its holdings in Bristol-Myers Squibb by 13.1% in the 1st quarter. FDx Advisors Inc. now owns 32,005 shares of the biopharmaceutical company's stock valued at $2,024,000 after buying an additional 3,695 shares during the last quarter. Hennessy Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the 1st quarter valued at approximately $5,882,000. Finally, Howland Capital Management LLC grew its holdings in Bristol-Myers Squibb by 18.2% in the 1st quarter. Howland Capital Management LLC now owns 50,352 shares of the biopharmaceutical company's stock valued at $3,185,000 after buying an additional 7,765 shares during the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors. Get Bristol-Myers Squibb alerts:
Shares of BMY stock opened at $61.11 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. Bristol-Myers Squibb Co has a 12 month low of $49.96 and a 12 month high of $70.05. The company has a market capitalization of $96.94 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 1.50 and a beta of 1.02. Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping the Zacks' consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The company had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same quarter last year, the company earned $0.74 EPS. The company's quarterly revenue was up 10.9% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, August 1st. Investors of record on Friday, July 6th were given a dividend of $0.40 per share. The ex-dividend date was Thursday, July 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.62%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 53.16%.
A number of analysts have issued reports on the company. Credit Suisse Group raised their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a "neutral" rating in a report on Friday, July 27th. ValuEngine raised Bristol-Myers Squibb from a "sell" rating to a "hold" rating in a report on Saturday, July 14th. BMO Capital Markets reaffirmed a "hold" rating and issued a $47.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, June 21st. Atlantic Securities upgraded Bristol-Myers Squibb from an "underweight" rating to a "neutral" rating and set a $57.00 price objective for the company in a research report on Wednesday, August 8th. Finally, Barclays reduced their price objective on Bristol-Myers Squibb from $65.00 to $55.00 and set an "equal weight" rating for the company in a research report on Friday, April 27th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the company's stock. Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus target price of $63.11.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Google Finance
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY). Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter 